FDA Clears Path For Genta’s Genasense In Chronic Lymphocytic Leukemia
Agency acknowledges complete response as an appropriate primary endpoint for study; needs confirmatory evidence.
Agency acknowledges complete response as an appropriate primary endpoint for study; needs confirmatory evidence.